Literature DB >> 21905448

Glioblastoma. Part II: Future directions.

Michael E Salacz1, Kenneth R Watson, David A Schomas.   

Abstract

Although uncommon, "brain cancer" is one of the most feared diseases that afflict human beings. While still regarded as one of the most deadly forms of primary malignant brain neoplasm, recent advances in the treatment of Glioblastoma Multiforme (GBM) have offered new hope for patients, families and clinicians. In the first part of this two-part evidence-based review, we focused on the multidisciplinary advances that have established the current standard of care practice in the management of GBM. The second part discusses ongoing research efforts, both ongoing clinical trial efforts as well as some of the newer technologies that are forming the promise of the future.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21905448      PMCID: PMC6188420     

Source DB:  PubMed          Journal:  Mo Med        ISSN: 0026-6620


  14 in total

1.  Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas.

Authors:  Shannon E Fogh; David W Andrews; Jon Glass; Walter Curran; Charles Glass; Colin Champ; James J Evans; Terry Hyslop; Edward Pequignot; Beverly Downes; Eileen Comber; Mitchell Maltenfort; Adam P Dicker; Maria Werner-Wasik
Journal:  J Clin Oncol       Date:  2010-05-17       Impact factor: 44.544

Review 2.  Hospital and physician volume or specialization and outcomes in cancer treatment: importance in quality of cancer care.

Authors:  B E Hillner; T J Smith; C E Desch
Journal:  J Clin Oncol       Date:  2000-06       Impact factor: 44.544

3.  Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial.

Authors:  Walter Stummer; Uwe Pichlmeier; Thomas Meinel; Otmar Dieter Wiestler; Friedhelm Zanella; Hans-Jürgen Reulen
Journal:  Lancet Oncol       Date:  2006-05       Impact factor: 41.316

4.  Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study.

Authors:  Seymur Gahramanov; Ahmed M Raslan; Leslie L Muldoon; Bronwyn E Hamilton; William D Rooney; Csanad G Varallyay; Jeffrey M Njus; Marianne Haluska; Edward A Neuwelt
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-04-13       Impact factor: 7.038

5.  Survival and quality of life after hypofractionated stereotactic radiotherapy for recurrent malignant glioma.

Authors:  Antje Ernst-Stecken; Oliver Ganslandt; Ulrike Lambrecht; Rolf Sauer; Gerhard Grabenbauer
Journal:  J Neurooncol       Date:  2006-09-20       Impact factor: 4.130

6.  Surgery guided by 5-aminolevulinic fluorescence in glioblastoma: volumetric analysis of extent of resection in single-center experience.

Authors:  Ricardo Díez Valle; Sonia Tejada Solis; Miguel Angel Idoate Gastearena; Reyes García de Eulate; Pablo Domínguez Echávarri; Javier Aristu Mendiroz
Journal:  J Neurooncol       Date:  2010-07-06       Impact factor: 4.130

7.  Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution.

Authors:  Stephanie E Combs; Christoph Thilmann; Lutz Edler; Jürgen Debus; Daniela Schulz-Ertner
Journal:  J Clin Oncol       Date:  2005-12-01       Impact factor: 44.544

8.  Surgery for primary supratentorial brain tumors in the United States, 1988 to 2000: the effect of provider caseload and centralization of care.

Authors:  Fred G Barker; William T Curry; Bob S Carter
Journal:  Neuro Oncol       Date:  2005-01       Impact factor: 12.300

9.  Five-aminolevulinic acid for fluorescence-guided resection of recurrent malignant gliomas: a phase ii study.

Authors:  Arya Nabavi; Holger Thurm; Basilios Zountsas; Thorsten Pietsch; Heinrich Lanfermann; Uwe Pichlmeier; Maximilian Mehdorn
Journal:  Neurosurgery       Date:  2009-12       Impact factor: 4.654

10.  Efficacy of stereotactic radiosurgery as a salvage treatment for recurrent malignant gliomas.

Authors:  Doo-Sik Kong; Jung-Il Lee; Kwan Park; Jong Hyun Kim; Do-Hoon Lim; Do-Hyun Nam
Journal:  Cancer       Date:  2008-05-01       Impact factor: 6.860

View more
  1 in total

1.  Overexpression of FZD7 promotes glioma cell proliferation by upregulating TAZ.

Authors:  Xia Qiu; Jianguo Jiao; Yidong Li; Tian Tian
Journal:  Oncotarget       Date:  2016-12-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.